Tags

Type your tag names separated by a space and hit enter

A random comparative study of terbinafine versus griseofulvin in patients with tinea capitis in Western China.
Mycopathologia. 2011 Nov; 172(5):365-72.M

Abstract

OBJECTIVE

To compare the efficacy and safety of terbinafine with griseofulvin in the treatment of tinea capitis in Western China.

METHODS

Children (2-14 years of age) with clinically diagnosed and potassium hydroxide microscopy-confirmed tinea capitis were randomized into three groups: group GRI4 received 4 weeks of griseofulvin; group TBF2 received 2 weeks of terbinafine; and Group TBF4 received 4 weeks of terbinafine. Clinical and mycological evaluations were done in 0, 2, 4, and 8 weeks and 1 year after therapy started. The isolated pathogenic fungi were evaluated for in vitro susceptibility by detecting the minimal inhibitory concentration (MIC) against terbinafine, griseofulvin, itraconazole, and ketoconazole.

RESULTS

The clinical effectiveness rate of GRI4, TBF2, and TBF4 were 100% (95% CI-confidence interval: 82-100%), 96.3% (95% CI: 81-100%), and 100%(95% CI: 85-100%), respectively, at week 8 and 100% after 1 year for the 3 groups; clinical cure rates were 84.2%(95% CI: 77-99%), 85.2%(95% CI: 71-98%), and 78.3%(95% CI: 61-95%), respectively, at week 8 and 100% after 1 year for all agents; mycological cure rates were 100%(95% CI: 74-100%), 95.0%(95% CI: 74-100%), and 94.1%(95% CI: 50-93%) at week 8 and 100% after 1 year for the 3 groups. In vitro, all patient-derived cultures were sensitive to the four antifungal agents.

CONCLUSION

Data from the clinical trial and in vitro antifungal activity indicated that terbinafine is efficacious and well tolerated in the treatment for Trichophyton infections (T. violaceum; Arthroderma vanbreuseghemii; and T. tonsurans) of the scalp, i.e., a 2- to 4-week course of terbinafine is as effective as a 4-week course of griseofulvin; in fact, a 2-week course of terbinafine is sufficient. Terbinafine is an effective alternative to griseofulvin against tinea capitis of Trichophyton infections.

Authors+Show Affiliations

Department of Dermatology, First Hospital and Xinjiang Medical University, Urumqi, Xinjiang Province, People's Republic of China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21701791

Citation

Deng, S, et al. "A Random Comparative Study of Terbinafine Versus Griseofulvin in Patients With Tinea Capitis in Western China." Mycopathologia, vol. 172, no. 5, 2011, pp. 365-72.
Deng S, Hu H, Abliz P, et al. A random comparative study of terbinafine versus griseofulvin in patients with tinea capitis in Western China. Mycopathologia. 2011;172(5):365-72.
Deng, S., Hu, H., Abliz, P., Wan, Z., Wang, A., Cheng, W., & Li, R. (2011). A random comparative study of terbinafine versus griseofulvin in patients with tinea capitis in Western China. Mycopathologia, 172(5), 365-72. https://doi.org/10.1007/s11046-011-9438-2
Deng S, et al. A Random Comparative Study of Terbinafine Versus Griseofulvin in Patients With Tinea Capitis in Western China. Mycopathologia. 2011;172(5):365-72. PubMed PMID: 21701791.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A random comparative study of terbinafine versus griseofulvin in patients with tinea capitis in Western China. AU - Deng,S, AU - Hu,H, AU - Abliz,P, AU - Wan,Z, AU - Wang,A, AU - Cheng,W, AU - Li,R, Y1 - 2011/06/24/ PY - 2010/08/17/received PY - 2011/06/08/accepted PY - 2011/6/25/entrez PY - 2011/6/28/pubmed PY - 2012/2/11/medline SP - 365 EP - 72 JF - Mycopathologia JO - Mycopathologia VL - 172 IS - 5 N2 - OBJECTIVE: To compare the efficacy and safety of terbinafine with griseofulvin in the treatment of tinea capitis in Western China. METHODS: Children (2-14 years of age) with clinically diagnosed and potassium hydroxide microscopy-confirmed tinea capitis were randomized into three groups: group GRI4 received 4 weeks of griseofulvin; group TBF2 received 2 weeks of terbinafine; and Group TBF4 received 4 weeks of terbinafine. Clinical and mycological evaluations were done in 0, 2, 4, and 8 weeks and 1 year after therapy started. The isolated pathogenic fungi were evaluated for in vitro susceptibility by detecting the minimal inhibitory concentration (MIC) against terbinafine, griseofulvin, itraconazole, and ketoconazole. RESULTS: The clinical effectiveness rate of GRI4, TBF2, and TBF4 were 100% (95% CI-confidence interval: 82-100%), 96.3% (95% CI: 81-100%), and 100%(95% CI: 85-100%), respectively, at week 8 and 100% after 1 year for the 3 groups; clinical cure rates were 84.2%(95% CI: 77-99%), 85.2%(95% CI: 71-98%), and 78.3%(95% CI: 61-95%), respectively, at week 8 and 100% after 1 year for all agents; mycological cure rates were 100%(95% CI: 74-100%), 95.0%(95% CI: 74-100%), and 94.1%(95% CI: 50-93%) at week 8 and 100% after 1 year for the 3 groups. In vitro, all patient-derived cultures were sensitive to the four antifungal agents. CONCLUSION: Data from the clinical trial and in vitro antifungal activity indicated that terbinafine is efficacious and well tolerated in the treatment for Trichophyton infections (T. violaceum; Arthroderma vanbreuseghemii; and T. tonsurans) of the scalp, i.e., a 2- to 4-week course of terbinafine is as effective as a 4-week course of griseofulvin; in fact, a 2-week course of terbinafine is sufficient. Terbinafine is an effective alternative to griseofulvin against tinea capitis of Trichophyton infections. SN - 1573-0832 UR - https://www.unboundmedicine.com/medline/citation/21701791/A_random_comparative_study_of_terbinafine_versus_griseofulvin_in_patients_with_tinea_capitis_in_Western_China_ L2 - https://dx.doi.org/10.1007/s11046-011-9438-2 DB - PRIME DP - Unbound Medicine ER -